Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever

Summary

This exploratory, prospective, controlled, multisite, open label, randomized clinical trial with two treatment arms aims to compare favipiravir, a new treatment candidate for Lassa fever (LF), with the current standard of care, ribavirin. The primary endpoints of this research are (1) the description of classical pharmacokinetic parameters of favipiravir in comparison with ribavirin standard treatment in patients suffering from LF and (2) the safety and tolerability of both study drugs in the investigated regimens.

Timeline

Start

2021-07-30

Primary completion

2022-11-10

Completion

2022-11-17

Publications

• Erameh C, Okwaraeke K, Kleist C, Edeawe O, Adedosu N, Ekata E, Abejegah C, Owhin S, Babatunde F, Omansen T, Meneguim A, Duvignaud A, Mischlinger J, Ithete N, Oestereich L, Hinzmann J, Ahmed L, Duraffour S, Eifedyi R, Okogbenin S, Akhideno P, Ayodeji OO, Gunther S, Wicha SG, Jaspard M, Pahlmann M, Ramharter M, Groger M. Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial. Nat Med. 2026 Jul;32(7):2522-2532. doi: 10.1038/s41591-026-04402-w. Epub 2026 May 15.

Drugs

Indications